集中暴露和反应预防对失眠症状的影响

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-07-01 DOI:10.1016/j.jocrd.2024.100891

Nils Eivind Holth Landrø , Sigurd Holmen Pryser , Kristen Hagen , Bjarne Hansen , Gerd Kvale , Stian Solem

{"title":"集中暴露和反应预防对失眠症状的影响","authors":"Nils Eivind Holth Landrø , Sigurd Holmen Pryser , Kristen Hagen , Bjarne Hansen , Gerd Kvale , Stian Solem","doi":"10.1016/j.jocrd.2024.100891","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Insomnia symptoms are prevalent among patients with obsessive-compulsive disorder (OCD). This study involved secondary analyses from a previous randomized controlled trial testing if <span>d</span>-Cycloserine (DCS) augmented the effects of the Bergen 4-day treatment (B4DT) for OCD. In this study, the effects of the B4DT on sleep difficulties in a sample of difficult-to-treat OCD were explored.</p></div><div><h3>Methods</h3><p>The three groups received B4DT with either a placebo, 100 mg, or 250 mg of DCS. Patients (<em>N</em> = 163) had either not responded or relapsed after previous exposure-based treatment for OCD.</p></div><div><h3>Results</h3><p>The results showed a small, but robust treatment effect on insomnia symptoms (<em>d</em> = 0.37), maintained at 3-month follow-up (<em>d</em> = 0.38), and 12-month follow-up (<em>d</em> = 0.23). No significant differences between the groups receiving DCS or placebo were found. Insomnia did not affect OCD-treatment outcome.</p></div><div><h3>Discussion</h3><p>This study showed that OCD treatment is associated with some improvement in insomnia symptoms. Comorbid insomnia and DCS did not moderate treatment outcome. Patients with OCD and comorbid insomnia should be considered for specific insomnia treatment.</p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211364924000356/pdfft?md5=2e087f2e4fae937ffe1e9b2ab43cf1f7&pid=1-s2.0-S2211364924000356-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Effect of concentrated exposure and response prevention on symptoms of insomnia\",\"authors\":\"Nils Eivind Holth Landrø , Sigurd Holmen Pryser , Kristen Hagen , Bjarne Hansen , Gerd Kvale , Stian Solem\",\"doi\":\"10.1016/j.jocrd.2024.100891\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Insomnia symptoms are prevalent among patients with obsessive-compulsive disorder (OCD). This study involved secondary analyses from a previous randomized controlled trial testing if <span>d</span>-Cycloserine (DCS) augmented the effects of the Bergen 4-day treatment (B4DT) for OCD. In this study, the effects of the B4DT on sleep difficulties in a sample of difficult-to-treat OCD were explored.</p></div><div><h3>Methods</h3><p>The three groups received B4DT with either a placebo, 100 mg, or 250 mg of DCS. Patients (<em>N</em> = 163) had either not responded or relapsed after previous exposure-based treatment for OCD.</p></div><div><h3>Results</h3><p>The results showed a small, but robust treatment effect on insomnia symptoms (<em>d</em> = 0.37), maintained at 3-month follow-up (<em>d</em> = 0.38), and 12-month follow-up (<em>d</em> = 0.23). No significant differences between the groups receiving DCS or placebo were found. Insomnia did not affect OCD-treatment outcome.</p></div><div><h3>Discussion</h3><p>This study showed that OCD treatment is associated with some improvement in insomnia symptoms. Comorbid insomnia and DCS did not moderate treatment outcome. Patients with OCD and comorbid insomnia should be considered for specific insomnia treatment.</p></div>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2211364924000356/pdfft?md5=2e087f2e4fae937ffe1e9b2ab43cf1f7&pid=1-s2.0-S2211364924000356-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2211364924000356\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211364924000356","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

背景强迫症（OCD）患者普遍存在失眠症状。本研究对之前的一项随机对照试验进行了二次分析，测试 d-环丝氨酸（DCS）是否能增强卑尔根 4 天疗法（B4DT）治疗强迫症的效果。在这项研究中，我们探讨了 B4DT 对难以治疗的强迫症样本中睡眠困难的影响。结果结果显示，对失眠症状的治疗效果虽小，但却很稳健（d = 0.37），并在 3 个月的随访（d = 0.38）和 12 个月的随访（d = 0.23）中保持不变。接受 DCS 或安慰剂治疗的两组之间没有发现明显差异。失眠并不影响强迫症的治疗效果。合并失眠和 DCS 并不影响治疗效果。患有强迫症并合并失眠的患者应考虑接受特定的失眠治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Effect of concentrated exposure and response prevention on symptoms of insomnia

Background

Insomnia symptoms are prevalent among patients with obsessive-compulsive disorder (OCD). This study involved secondary analyses from a previous randomized controlled trial testing if d-Cycloserine (DCS) augmented the effects of the Bergen 4-day treatment (B4DT) for OCD. In this study, the effects of the B4DT on sleep difficulties in a sample of difficult-to-treat OCD were explored.

Methods

The three groups received B4DT with either a placebo, 100 mg, or 250 mg of DCS. Patients (N = 163) had either not responded or relapsed after previous exposure-based treatment for OCD.

Results

The results showed a small, but robust treatment effect on insomnia symptoms (d = 0.37), maintained at 3-month follow-up (d = 0.38), and 12-month follow-up (d = 0.23). No significant differences between the groups receiving DCS or placebo were found. Insomnia did not affect OCD-treatment outcome.

Discussion

This study showed that OCD treatment is associated with some improvement in insomnia symptoms. Comorbid insomnia and DCS did not moderate treatment outcome. Patients with OCD and comorbid insomnia should be considered for specific insomnia treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.

期刊最新文献

Management of Cholesteatoma: Hearing Rehabilitation. Congenital Cholesteatoma. Evaluation of Cholesteatoma. Management of Cholesteatoma: Extension Beyond Middle Ear/Mastoid. Recidivism and Recurrence.